Abstract The objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway in the response to treatment with olmesartan, an angiotensin II type 1 receptor blocker. Male Wistar albino rats were randomly divided into five groups of ten rats each: (1) non-ligature with water, (2) ligature with water, (3) ligature with 1 mg/kg olmesartan, (4) ligature with 6 mg/kg olmesartan, and (5) ligature with 10-mg/kg olmesartan. All groups were treated with olmesartan or the vehicle by gavage daily for 10 days. Following the treatment course, the periodontal tissue of the animals was analyzed by histopathology and immunohistochemistry to determine the expression of cyclooxygenase-2 (COX-2), MMP-2, MMP-9, and members of the RANKL/RANK/OPG pathway and by ELISA and spectroscopic assay to determine the levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, myeloperoxidase (MPO), malonaldehyde (MDA), and glutathione. The concentrations of MPO and MDA were reduced in the group that received 6 mg/kg olmesartan (p<0.05). In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1β (p<0.05), and all doses of olmesartan resulted in decreased levels of TNF-α. Furthermore, treatment with 6 mg/kg olmesartan led to downregulation of the expression of COX-2, MMP-2, MMP-9, RANKL, and RANK and to upregulation of the expression of OPG. These findings suggest that 6 mg/kg olmesartan reduces the inflammatory process and bone loss by downregulating MMPs and RANKL in osteoblasts and by upregulating OPG.
Introduction
Periodontitis is a chronic inflammatory disease resulting from the perturbed homeostasis between the subgingival microbiota and the host defenses (Sanz and van Winkelhoff 2011) . Lipopolysaccharides that are derived from plaque biofilms on the tooth root surface recruit polymorphonuclear leukocytes to the site. Monocytes and activated macrophages respond by releasing various proinflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor (TNF)-α, which, in turn, direct further destructive processes (Giannobile 2008) .
Recently, the mechanisms of bone resorption have been actively examined, and the discovery of the receptor activator of NF-κB (RANK) ligand has allowed elucidation of the mechanisms of osteoclast differentiation in the bone. Osteoblasts express the RANK ligand (RANKL) as a membrane-associated factor in response to various bone-resorbing factors such as parathyroid hormone, IL-1, and prostaglandin E2 (PGE2). Osteoclast precursors express RANK, a receptor for RANKL, and the recognition between RANK and RANKL induces the differentiation of the precursors into osteoclasts (Harada and Takahashi 2011) .
Another mechanism of bone resorption involves matrix metalloproteinases (MMPs), which are a family of proteolytic enzymes that degrade proteins of the extracellular matrix of various tissues including the bone. More than 20 different mammalian MMPs have been identified, and these have been divided into four subgroups: collagenases (MMP-1, MMP-8, MMP-13, and MMP-18), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3 and MMP-10), and membrane-type metalloproteinases (MMPs-14-17) (Vargova et al. 2012) . Osteoblasts are known to express various MMPs such as MMP-1, MMP-2, MMP-13 (collagenase 3), and MMP-14 (MT1-MMP), and they selectively produce MMP-9 (Vargova et al. 2012) . The induction of specific MMPs (such as MMP-2, MMP-3, and MMP-13) in osteoblasts is reported to be essential for bone resorption (Kusano et al. 1998) .
Treatments for periodontitis have been investigated, and a variety of host modulatory therapies for periodontitis now exist, including the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (Kirkwood et al. 2007) .
Olmesartan, an angiotensin II type 1 receptor blocker, has also been investigated and found to inhibit the expression of TNF-α (Li et al. 2004 ). The mechanism of inhibiting the expression of TNF-α by olmesartan-induced can be very interesting to study in the context of periodontal disease because studies have shown, beyond doubt, that the plaque bacteria that are necessary for initiating periodontal disease drive a chronic inflammatory response in periodontal tissues (Deo and Bhongade 2010; de Molon et al. 2012) . Strong evidence indicates that this host inflammatory response leads to destructive processes that are responsible for the majority of the hardand soft-tissue breakdown that leads to the clinical signs of periodontitis. The characteristic clinical signs of chronic periodontitis occur mainly as a result of the activation of hostderived immune and inflammatory defense mechanisms. Both IL-1 and TNF-α induce the expression of other mediators, such as prostaglandins, that amplify the inflammatory response, lead to the production of lytic enzymes, and stimulate the production of chemokines (Deo and Bhongade 2010) . Investigation of the action of olmesartan in an experimental model for periodontal disease is an important and necessary step that we must perform prior to entering into clinical trials to determine whether olmesartan can reduce the severity of periodontal disease.
The objective of the study is to investigate the participation of the inflammatory mediators (myeloperoxidase (MPO), cyclooxygenase-2 (COX-2), IL-1β, IL-10, and TNF-α), oxidation mediators (malonaldehyde (MDA) and glutathione (GSH)), and bone-remodeling proteins (MMP-2, MMP-9, RANK, RANKL, and osteoprotegerin (OPG)) in olmesartan treatment in a rat model for periodontal disease.
Materials and methods

Animals
Diet information: Experiments were performed on male Wistar rats (180-220 g) housed in standard conditions (12-h light/dark cycle and 22±0.1°C), with ad libitum access to water and a standard diet (basic composition: soybean meal, dextrin, rice husks, wheat bran, rice bran, meat meal, fish meal, sodium chloride, magnesium oxide, iron sulfate, copper sulfate, manganese monoxide, zinc oxide, calcium iodate, cobalt sulfate, sodium selenite, vitamin A, vitamin D3, vitamin E, vitamin K3, vitamin B1, vitamin B2, niacin, pantothenic acid, vitamin B6, folic acid, biotin, vitamin B12 , choline chloride, lysine, methionine, propionic acid, Agrobacterium tumefaciens, and Bacillus thuringiensis; Presence/Evialis do Brasil Nutrição Animal Ltda, São Paulo). The rats were fasted 12 h before sacrifice. The experimental protocol for experimental procedures and animal treatment was approved by the Animal Ethics Committee (number 28/2012) of the Federal University of Rio Grande Norte.
Model for EPD
Experimental periodontitis (EPD) was induced in rats under anesthesia induced by ketamine (70 mg/kg administered i.p., 10 % Quetamina, Vetnil, São Paulo) and xylazine (10 mg/kg administered i.p., 2 % Calmium, São Paulo) by the placement of a sterile nylon thread ligature (3-0; Polysuture, NP45330, São Paulo) around the cervix of the maxillary left second molar (Carvalho et al. 2010) . Eleven days after the initial treatment, the animals were euthanized with 20 mg/kg thiopental (0.5 g Thiopentax, Cristália, São Paulo).
Drug treatments
For treatments, olmesartan medoxomil (Benicar 20 mg, Daiichi Sankyo Brasil Farmacêutica Ltda, São Paulo, Brazil) was solubilized in distilled water (vehicle). All treatments (olmesartan or vehicle) were given orally by gavage 1 h before ligation (induction of EPD) and there after once daily for 10 days. The animals were assigned randomly to the following five groups, with ten animals per group: (1) a non-ligated group that received water (NL), (2) a ligated group that received water (L), (3) a ligated group treated with 1 mg/kg olmesartan (OLME 1 mg/kg), (4) a ligated group treated with 6 mg/kg olmesartan (OLME 6 mg/kg), and (5) a ligated group treated with 10 mg/kg olmesartan (OLME 10 mg/kg).
Measurement of alveolar bone loss
The excised maxillae were fixed in 10 % neutral formalin for 24 h. Both maxillary halves were then defleshed and stained with aqueous methylene blue (1 %) to differentiate the bone from the tooth. Measurements of bone loss were made along the axis of each root surface of all molar teeth. Three recordings were made for the first molar teeth (three roots each) and two recordings for the second and third molar teeth (two roots each).The total alveolar bone loss was obtained by taking the sum of the recordings from the buccal tooth surfaces and subtracting the values of the right maxilla (unligated control) from the left maxilla, in millimeters (Carvalho Rde et al. 2013) . Morphometric analysis of the alveolar bone was performed with standardized digital photography (Olympus SC30), and the distance (millimeters) was measured with image software (analysis getIT 5.1).
Histopathological analysis
The immunohistochemical analysis and the histological scores of the periodontal tissues were conducted by two calibrated oral pathologists. The sectioning was performed in the Laboratory of Morphology and Oral Pathology and subsequently analyzed by light microscopy in the Department of Morphology, UFRN. Alveolar bone specimens were harvested, fixed in 10 % neutralbuffered formalin, and demineralized in 5 % nitric acid. Following these treatments, the specimens were dehydrated, embedded in paraffin, and sectioned along the molars in a mesiodistal plane for hematoxylin-eosin staining. Sections of 4-μm thickness, corresponding to the area between the first and second molars where the ligature had been placed, were evaluated by light microscopy (×40 magnification). Parameters such as inflammatory cell influx and the integrity of the alveolar bone and the cementum were analyzed by a histologist in a single-blind fashion and graded as follows: a score of 0 indicates that inflammatory cell infiltration is absent or sparse and is restricted to the region of the marginal gingiva and that the alveolar process and cementum are preserved; a score of 1 indicates moderate cellular infiltration (inflammatory cellular infiltration present on the entire gingival insert), minor alveolar process resorption, and an intact cementum; a score of 2 indicates accentuated cellular infiltration (inflammatory cellular infiltration present in the gingiva and in the periodontal ligament), accentuated degradation of the alveolar process, and partial destruction of the cementum; and a score of 3 indicates accentuated cellular infiltration, complete resorption of the alveolar process, and severe destruction of the cementum (Leitao et al. 2005 ).
Immunohistochemical analysis of COX-2, MMP-2, MMP-9, RANKL, RANK, and OPG Thin sections of periodontal tissue (4 μm) were obtained with a microtome and were transferred to gelatin-coated slides. Each tissue section was then deparaffinized and rehydrated. The gingival and periodontal tissues slices were washed with 0.3 % Triton X-100 in phosphate buffer, were quenched with endogenous peroxidase (3 % hydrogen peroxide), and were incubated with the following primary antibodies (purchased from Santa Cruz Biotechnology) overnight at 4°C: COX-2, 1:400; MMP-2, 1:400; MMP-9, 1:400; RANKL, 1:400; RANK, 1:400; and OPG, 1:400. After the slices were washed with phosphate buffer, they were incubated with a streptavidin-horseradish peroxidase (HRP)-conjugated secondary antibody (Biocare Medical) for 30 min, and immunoreactivity to COX-2, MMP-2, MMP-9, RANK, RANKL, and OPG was visualized using a colorimetric-based detection kit following the protocol provided by the manufacturer (TrekAvidin-HRP Label + Kit from Biocare Medical, Dako, USA).
MPO assay
The extent of neutrophil accumulation in the gingival samples was measured by assaying MPO activity. Gingival samples were harvested as described above and stored at −70°C until required for the assay. After homogenization and centrifugation (2,000×g for 20 min), MPO activity in these samples was determined by a colorimetric method described previously (Souza et al. 2003) . The results were reported as units of MPO per milligram of tissue.
MDA levels
To assess lipid peroxidation, MDA production was measured with a thiobarbituric acid reaction in gingival tissue from the rats. Gingival tissue homogenate (0.25 ml of 10 % tissue prepared in 0.15 M KCl) was added to a thiobarbituric acid solution (1.5 ml of 1 % H 3 PO 4 and 500 μl of a 0.6 % thiobarbituric acid aqueous solution), and the mixture was placed in a water bath and heated for 45 min at 100°C. Next, 2 ml of n-butanol PA was added, and the mixture was homogenized and then centrifuged at 12,000 rpm for 15 min at 4°C. The absorbance of the butanol layer was measured at 520 nm (A1) and 535 nm (A2) (GENESYS 10S UV-Vis, Thermo Scientific, England). The concentration of malonaldehyde was calculated as A2−A1, expressed as nanomoles of MDA per gram of gingival tissue.
GSH assay GSH levels in gingival tissue were measured as a marker for antioxidant activity. The gingival samples were removed and stored at −70°C until required for the assay. Gingival tissue homogenate (0.25 ml of a 5 % tissue solution prepared in 0.02 M EDTA) was added to 320 μl of distilled water and 80 μl of 50 % TCA. The samples were then centrifuged at 3,000 rpm for 15 min at 4°C. The supernatant (400 μl) was added to 800 μl of 0.4 M Tris buffer at pH 8.9 and 20 μl of 0.01 M DTNB. The absorbance of each sample was measured at 420 nm, and the results were reported as units of MPO per milligram of tissue.
IL-1β, IL-10, and TNF-! assay
The gingival sample tissues were stored at −70°C until required for each assay. The tissue collected was homogenized and processed as described by Safieh-Garabedian et al. (1995) . The levels of IL-1β, IL-10, and TNF-α in the gingival samples were determined with an ELISA commercial kit (R&D Systems, EUA) as described previously (Kendall et al. 1983) . Briefly, microtiter plates were coated overnight at 4°C with antibodies against mouse TNF-α, IL-1β, and IL-10. After the plates were blocked, the samples and standards were added at various dilutions in duplicate and incubated at 4°C for 24 h. The plates were washed three times with buffer. The following antibodies were then added to the wells: biotinylated sheep polyclonal anti-TNF-α, anti-IL-1β, or anti-IL-10 (diluted 1:1,000 with 1 % BSA assay buffer). After further incubation at room temperature for 1 h, the plates were washed and 50 μl of avidin-HRP (diluted 1:5,000) was added. The color reagent o-phenylenediamine (50 μl) was added 15 min later, and the plates were incubated in the dark at 37°C for 15-20 min. The enzyme reaction was stopped with H 2 SO 4 , and absorbance was measured at 490 nm. The resulting values were expressed in picograms per milliliter.
Statistical analysis
The data are presented as mean + standard error of the mean (SEM) or as medians, where appropriate. ANOVA followed by Bonferroni test was used to calculate the means, and the Kruskal-Wallis test followed by Dunn's test was used to compare medians (GraphPad Prism 5.0 Software). A P value of <0.05 was considered to indicate a significant difference. 
Results
Effect of olmesartan treatment on alveolar bone loss in rats with EPD Rats with EPD (L) showed a significant alveolar bone loss compared to NL (NL=1.4±0.07 mm; L=7.02±0.17 mm; p<0.001). It was observed that treatment with olmesartan 6 mg/kg reverse the alveolar bone loss caused by EPD (OLME 6 mg/kg, 4.03±0.17; p<0.05) (Fig. 1) . Rats with 1 and 10 mg/kg olmesartan no showed different significant alveolar bone loss compared to L (L= 7.02 ± 0.17 mm; OLME 1 mg/kg=5.9±1.0 mm; OLME 10 mg/kg=6.0±1.1-mm; p>0.05), Fig. 1 .
Dates are shown in Fig. 2a , which shows the macroscopic aspects of NL group with no resorption of the alveolar bone when compared to the L group (EPD), where severe bone resorption with root exposure is observed (Fig. 2b) . Figure 2c shows the macroscopic appearance of periodontium subjected to EPD and treated with olmesartan 6 mg/kg, where decreased bone loss is observed.
Histopathological analysis EPD-induced animals that were treated with 6 mg/kg olmesartan displayed reduced alveolar bone loss compared to those the EPD-induced animals that were treated with 1 and 10 mg/kg olmesartan and group periodontal disease (L) (p<0.05). The group periodontal disease (L) was assigned a median score of 3 (range 3-3) (p<0.05) ( Table 1 ). The animals in the group treated with 6 mg/kg olmesartan received a median score of 2 (range 2-3) ( Table 1) . The group treated with 1 and 10 mg/kg received a median score 3 (range 3-3; p<0.05) and 3 (range 2-3), respectively. Histopathological analysis shows discrete cellular infiltration (restricted to the region of the marginal gingival) and a preserved alveolar process and cementum in the group treated with olmesartan (6 mg/kg) (Fig. 4c) . In addition, microscopic images illustrate the reduction of inflammation and alveolar bone loss in the periodontia of rats treated with 6 mg/kg olmesartan. Histopathological analysis of the region between the first and second molars of the NL group indicates that the periodontia of this group are normal, specifically the gingiva, periodontal ligament, alveolar bone, and cementum (Figs. 3,  4 , and 5a). The periodontia of the EPD-induced (L) animals exhibited inflammatory cell infiltration coupled with severe destruction of the cementum and of the alveolar process (Figs. 3, 4 , and 5b). Inflammation and alveolar bone loss in the periodontium of rats treated with olmesartan (1 mg/kg, Fig. 3c ; 10 mg/kg, Fig. 5c ) for 10 days. The animals exhibited inflammatory cell infiltration coupled with severe destruction of the cementum and of the alveolar process.
Immunohistochemical analysis of markers of inflammation and bone-remodeling proteins
The periodontia of EPD-induced rats (L) showed markedly increased immunostaining for COX-2, MMP-2, MMP-9, RANKL, and RANK (Fig. 6b , e, h, k, n) compared to the periodontia of the NL group (Fig. 6a, d , g, j, m). Olmesartan (6 mg/kg) reduced the amount of immunostaining observed for COX-2, MMP-2, MMP-9, RANKL, and RANK in the periodontia of the EPD-induced rats (Fig. 6c, f, i, l, o) . Immunostaining for OPG was low in the periodontia of the L group (Fig. 6q) , moderate in the NL group (Fig. 6p) , and intense in the group treated with 6 mg/kg olmesartan (Fig. 6r) . Fig. 3 Microscopic analysis. a Normal periodontium (non-ligated group). b Periodontium (ligated group) from a rat presenting with periodontitis (treated with saline) showing alveolar bone and cementum resorption and inflammatory cell infiltration. c Inflammation and alveolar bone loss in the periodontium of rats treated with olmesartan (1 mg/ kg) for 10 days. Sections were stained with H&E. Microscopic original magnification at ×40. Scale bars=100 μm. G gingiva, PL periodontal ligament, D dentin, AB alveolar bone, C cementum, a bone loss, b resorption of cementum, c inflammatory process, e, f inflammation process and bone loss (Natal, RN, 2013) NL L OLME 1 mg/kg OLME 6 mg/kg OLME 10 mg/kg 0 (0-0) 3 (3-3)* 3 (3-3)* 2 (2-3) 3 (2-3)
Effect of olmesartan on inflammatory activity
The group treated with 6 mg/kg olmesartan showed a reduced concentration of MPO (Fig. 7 ) compared to L group (p<0.01) and a reduced level of the proinflammatory cytokine IL-1β (Fig. 8) (p<0.05) . The group treated with 1 and 10 mg/kg olmesartan did not show a reduced concentration of MPO and level of cytokine IL-1β compared to L group (p>0.05) (Fig. 7) . The levels of TNF-α were reduced in all doses of olmesartan treatment compared to the L group (Fig. 8) .
Effect of olmesartan on oxidative stress
Treatment with 6 mg/kg olmesartan reduced the activity of MDA (p < 0.01), while treatment with 1 and 10 mg/kg olmesartan reduced the activity of MDA (p<0.05). The levels of GSH did not increase in the olmesartan-treated animals compared to the group that was subjected to EPD and treated with vehicle (p>0.05) (Fig. 7) .
Discussion
Improved knowledge of the pathogenesis of periodontal disease, including better elucidation of the host mechanisms that participate in the development of the disease, has resulted in the proposal of novel agents aimed at modulating the host response by inhibiting inflammatory mediators. According to Grenier et al. (2002) , NSAIDs inhibit the formation of prostaglandins, including PGE2. The level of PGE2 has been observed to be increased in periodontal disease compared to that in healthy patients, but studies have shown an increase in bone loss and fracture risk in patients Fig. 5 Microscopic analysis. a Normal periodontium (non-ligated group). b Periodontium from a rat presenting with periodontitis (treated with saline) showing alveolar bone and cementum resorption and inflammatory cell infiltration. c Inflammation and alveolar bone loss in the periodontium of rats treated with olmesartan (10 mg/kg) for 10 days. Sections were stained with H&E. Microscopic original magnification at ×40. Scale bars=100 μm. G gingiva, PL periodontal ligament, D dentin, AB alveolar bone, C cementum, a bone loss, b resorption of cementum, c inflammatory process, e, f inflammation process and bone loss Fig. 4 Microscopic analysis. a Normal periodontium (non-ligated group). b Periodontium ligated group from a rat presenting with periodontitis (treated with saline) showing alveolar bone and cementum resorption and inflammatory cell infiltration. c Reduced inflammation and alveolar bone loss in the periodontium of rats treated with olmesartan (10 mg/kg) for 10 days. Sections were stained with H&E. Microscopic original magnification at ×40. Scale bars=100 μm. G gingiva, PL periodontal ligament, D dentin, AB alveolar bone, C cementum, a bone loss, b resorption of cementum, c inflammatory process, e, f decreased inflammation process and bone loss that have used NSAIDs (Vestergaard et al. 2012; Richards et al. 2006) . Another treatment, celecoxib (an NSAID/COX-2 inhibitor), can be an effective adjunctive treatment in conjunction with scaling and root planning to reduce progressive attachment loss in subjects with chronic periodontitis. The beneficial effect of this drug persisted even at 6 months postadministration. However, given the increased cardiovascular risks associated with the use of this drug, close patient supervision and strict adherence to dosage and administration guidelines established by the US Food and Drug Administration are of paramount importance (Yen et al. 2008) . Various treatment strategies have been developed to target the host response for the management of periodontitis. MMP inhibitors such as lowdose formulations of doxycycline (Gapski et al. 2004 ) and pharmacologic inhibitors of NF-κB and p38 mitogenactivating protein kinase pathways are actively being developed to manage inflammatory bone diseases (Adams et al. 2001) . In a susceptible host, an overreaction of the host response occurs, resulting in the excessive production of proinflammatory cytokines such as IL-1, TNF-α, and IL-6, resulting in the loss (Grenier et al. 2002) of periodontal attachment (Gemmell et al. 1997) . Pharmacological inhibitors of inflammatory mediators such as proinflammatory cytokines (IL-1, TNF, and IL-6) and MMPs act upon cell signaling pathways that are required for the Fig. 6 Photomicrographs of the periodontal tissue of rats on EPD that were treated with olmesartan showing immunoreactivity to MMP-2, MMP-9, COX-2, RANK, RANKL, and OPG. Rats that were subjected to saline treatment (non-ligated group) are shown in a, d, g, j, m, and p; rats that were subjected to EPD (ligated group) are shown in b, e, h, k, n, and q; and rats subjected to EPD and treated with 6 mg/kg olmesartan are shown in c, f, i, l, o, and r. (×100 magnification; scale bar=100 μm) transcription factor activation that is necessary for the stability of the inflammatory response.
In this study, the major activity observed to be affected by olmesartan treatment was the inflammatory response, with significantly lower levels of IL-1β and TNF-α observed following treatment of animals with 6 mg/kg olmesartan. A previous study by Aki et al. (2010) showed that high-dose olmesartan treatment induced the augmentation of M2 macrophages in vivo and inhibited glomerular inflammation. Therefore, a high dose of olmesartan may have a therapeutic effect in cases of severe glomerulonephritis that are accompanied by extensive glomerular inflammation; olmesartan exerts these effects not only by inhibiting macrophage infiltration and M1 macrophage differentiation but also by enhancing the number of M2 macrophages, and thus the availability of antiinflammatory mediators (Aki et al. 2010) . We believe that the bone loss observed in the group treated with 10 mg/kg olmesartan is supported by published data claiming that olmesartan acts as a potent antifibrotic drug to suppress proliferation, collagen synthesis, and the expression of profibrogenic cytokines in activated HSCs by blocking angiotensin II type 1 receptor (Kurikawa et al. 2003) . On the other hand, a study performed in vitro showed that angiotensin (Ang) II accelerates osteoporosis by activating osteoclasts through the induction of RANKL. An Ang II type 1 receptor blockade such as olmesartan might become a novel therapeutic approach to prevent osteoporosis in hypertensive patients (Shimizu et al. 2008) . The next step of our research group will be to examine, in hypertensive animals, whether reduction of bone loss occurs with a dose of 10 mg/kg and whether this reduction in bone loss can be maintained with a subsequent dose of 6 mg/kg. The anti-inflammatory activity of olmesartan was also observed in an experiment conducted in an animal model for acute myocardial infarction; in this study, a reduction was observed in the levels of TNF-α, IL-1β, and IL-6. (Sandmann et al. 2006 ). In the periodontium, the activation of IL-1β and TNF-α is known to stimulate the degradation of connective tissue matrix, the activation of osteoclasts, and the resorption of bone (Graves et al. 2011; Graves 2008) . IL-1 induces the release of MMPs, whereas TNF-α, which is present in inflamed gingival tissue, is involved in the destruction of tissue (Yamaguchi and Kasai 2005) . These cytokines play key roles in the breakdown of periodontal tissue through collagenolytic enzymes such as MMPs. The inflamed tissue also expresses COX enzymes, which may play a role in the formation of arachidonic acid metabolites.
MMPs are a group of proteolytic enzymes that mediate the degradation of extracellular matrix macromolecules, including interstitial and basement collagens, fibronectin, laminin, and proteoglycan core proteins. The excessive production of MMPs leads to accelerated matrix degradation, a condition that is associated with pathological conditions such as periodontitis (Rutkowski et al. 2012) . Osteoblasts produce various MMPs such as MMP-1, MMP-2, MMP-13 (collagenase 3), and MMP-14 (MT1-MMP), and they selectively produce MMP-9. The induction of specific MMPs (such as MMP-2, MMP-3, and MMP-13) in osteoblasts is essential for bone resorption (Kusano et al. 1998) . In the present study, the downregulation of MMP-2 and MMP-9 was found following the treatment of animals with 6 mg/kg olmesartan.
Osteoblasts express RANKL as a membrane-associated factor in response to bone-resorbing factors such as IL-1β. The proteolytic cleavage of RANKL requires the participation of MMPs (Lynch et al. 2005) . RANKL expression is stimulated in osteoblasts and stromal cells by many of the same factors that are known to induce osteoclast formation and activity. Osteoclast precursors express RANK, which is a receptor for RANKL, and RANK-RANKL recognition induces the differentiation of the precursors into osteoclasts (Harada and Takahashi 2011) .
In addition, osteoblasts express OPG, and this expression is regulated by most of the factors that induce RANKL expression in these cells. During the differentiation into osteoclasts, the upregulation of RANKL is associated with the downregulation of OPG, or at least the reduced induction of OPG, such that the ratio of RANKL to OPG changes in favor of osteoclastogenesis (Theoleyre et al. 2004; Lossdorfer et al. 2011) .
In this study, olmesartan was found to reduce the expression of MMPs. In addition, a reduction was observed in the expression of RANKL in periodontal tissues following treatment with olmesartan, corresponding to an increase in the expression of OPG. These observations confirm the expression patterns of these proteins during the process of bone absorption/resorption.
Based on the findings presented here, it can be concluded that the use of olmesartan in a rat periodontal disease model reduces the inflammatory process and, hence, reduces the expression of MMPs and RANK/RANKL. Thus, the use of olmesartan in hypertensive patients may have beneficial effects on the progression of periodontal disease, reducing inflammation and metalloproteinases, as well as on the formation and differentiation of osteoclasts, confirmed by decreased expression of RANK/RANKL.
